Literature DB >> 9864176

Hyperdiploid acute lymphoblastic leukemia with 51 to 65 chromosomes: a distinct biological entity with a marked propensity to undergo apoptosis.

C Ito1, M Kumagai, A Manabe, E Coustan-Smith, S C Raimondi, F G Behm, K G Murti, J E Rubnitz, C H Pui, D Campana.   

Abstract

To determine the cellular basis for the excellent clinical outcome of hyperdiploid acute lymphoblastic leukemia (ALL), defined by a modal chromosome number of 51 to 65, we assessed the growth potential of leukemic cells from 129 children with newly diagnosed ALL. Flow cytometric analysis was used to compare leukemic cell recoveries at the beginning and at the end of 7-day cultures on allogeneic bone marrow-derived stromal layers. The median percentage of cell recovery after culture was 91% (range, <1% to 550%). Among the 25 hyperdiploid cases, only two had cell recoveries above the median value, compared with 63 of 104 cases with different ploidies (P <.001); 21 had recoveries within the first quartile, in contrast to only 12 of the 104 other cases. Cell recoveries in the 16 cases with duplications of chromosomes 4 and 10, a feature previously associated with a superior outcome, were all within the first quartile. Flow cytometric studies indicated that rapid induction of apoptosis was the underlying cause of low cell recoveries in cases with hyperdiploidy. The demise of hyperdiploid cells on stroma was not due to failure to adhere with stromal elements (as shown by electron microscopy) or to deficiencies of interleukin-1 (IL-1), IL-2, IL-3, IL-4, IL-6, IL-7, IL-11, stem-cell factor, interferon- (IFN-), tumor necrosis factor- (TNF-), or to combinations of these cytokines. Inactivation of IL-4, IFN- and TNF-, which if secreted by stromal layers could be toxic to ALL cells, failed to improve the survival of hyperdiploid blasts. We conclude that leukemic cells bearing 51 to 65 chromosomes have a marked propensity to undergo apoptosis. The stringent survival requirements of these cells, together with their potentially higher sensitivity to antileukemic drugs, may well account for the high cure rates achieved in patients with this form of ALL.

Entities:  

Mesh:

Year:  1999        PMID: 9864176

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  18 in total

Review 1.  Molecular pharmacodynamics in childhood leukemia.

Authors:  R Pieters; M L den Boer
Journal:  Int J Hematol       Date:  2003-12       Impact factor: 2.490

2.  Promoter hypermethylation of p73 and p53 genes in cervical cancer patients among north Indian population.

Authors:  Abhimanyu Kumar Jha; Mohsen Nikbakht; Veena Jain; Alka Sehgal; Neena Capalash; Jagdeep Kaur
Journal:  Mol Biol Rep       Date:  2012-06-24       Impact factor: 2.316

3.  Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cells.

Authors:  Chihaya Imai; Shotaro Iwamoto; Dario Campana
Journal:  Blood       Date:  2005-03-08       Impact factor: 22.113

4.  Genes contributing to minimal residual disease in childhood acute lymphoblastic leukemia: prognostic significance of CASP8AP2.

Authors:  Christian Flotho; Elaine Coustan-Smith; Deqing Pei; Shotaro Iwamoto; Guangchun Song; Cheng Cheng; Ching-Hon Pui; James R Downing; Dario Campana
Journal:  Blood       Date:  2006-04-20       Impact factor: 22.113

5.  The expression of 70 apoptosis genes in relation to lineage, genetic subtype, cellular drug resistance, and outcome in childhood acute lymphoblastic leukemia.

Authors:  Amy Holleman; Monique L den Boer; Renée X de Menezes; Meyling H Cheok; Cheng Cheng; Karin M Kazemier; Gritta E Janka-Schaub; Ulrich Göbel; Ulrike B Graubner; William E Evans; Rob Pieters
Journal:  Blood       Date:  2005-09-27       Impact factor: 22.113

6.  Predisposing germline mutations in high hyperdiploid acute lymphoblastic leukemia in children.

Authors:  Adam J de Smith; Geneviève Lavoie; Kyle M Walsh; Sumeet Aujla; Erica Evans; Helen M Hansen; Ivan Smirnov; Alice Y Kang; Martin Zenker; John J Ceremsak; Elliot Stieglitz; Ivo S Muskens; William Roberts; Roberta McKean-Cowdin; Catherine Metayer; Philippe P Roux; Joseph L Wiemels
Journal:  Genes Chromosomes Cancer       Date:  2019-05-27       Impact factor: 5.006

7.  [Effects of antihyperglycemics on endothelial progenitor cells].

Authors:  Xue Han; Guojun Jiang; Qiaojuan Shi
Journal:  Zhejiang Da Xue Xue Bao Yi Xue Ban       Date:  2020-10-25

8.  Impact of cytogenetics on the outcome of adult acute lymphoblastic leukemia: results of Southwest Oncology Group 9400 study.

Authors:  Vinod Pullarkat; Marilyn L Slovak; Kenneth J Kopecky; Stephen J Forman; Frederick R Appelbaum
Journal:  Blood       Date:  2007-12-21       Impact factor: 22.113

9.  Temporal changes in the incidence and pattern of central nervous system relapses in children with acute lymphoblastic leukaemia treated on four consecutive Medical Research Council trials, 1985-2001.

Authors:  S Krishnan; R Wade; A V Moorman; C Mitchell; S E Kinsey; T O B Eden; C Parker; A Vora; S Richards; V Saha
Journal:  Leukemia       Date:  2009-12-17       Impact factor: 11.528

10.  Rare and recurrent chromosomal abnormalities and their clinical relevance in pediatric acute leukemia of south Indian population.

Authors:  Seyed Hashem Mir Mazloumi; Prasanna Kumari; D S Madhumathi; L Appaji
Journal:  Indian J Med Paediatr Oncol       Date:  2012-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.